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Tyrosine kinase inhibitors (TKIs) are anti-cancer drugs that target tyrosine kinases,
enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs
have been introduced in the treatment of solid tumours, all administered in a fixed
dose, although large interpatient pharmacokinetic (PK) variability is described. For
imatinib, sunitinib and pazopanib exposure-treatment outcome (efficacy and toxicity)
relationships have been established and therapeutic windows have been defined,
therefore dose optimization based on the measured blood concentration, called ther-
apeutic drug monitoring (TDM), can be valuable in increasing efficacy and reducing
the toxicity of these drugs.
In this review, an overview of the current knowledge on TDM guided individualized
dosing of imatinib, sunitinib and pazopanib for the treatment of solid tumours is pres-
ented. We summarize preclinical and clinical data that have defined thresholds for
efficacy and toxicity. Furthermore, PK models and factors that influence the PK of
these drugs which partly explain the interpatient PK variability are summarized.
Finally, pharmacological interventions that have been performed to optimize plasma
concentrations are described. Based on current literature, we advise which methods
should be used to optimize exposure to imatinib, sunitinib and pazopanib.
K E YWORD S
anticancer drugs, pharmacodynamics, pharmacokinetics, therapeutic drug monitoring
1 | INTRODUCTION
Tyrosine kinases are the targets for anti-cancer drugs called
tyrosine kinase inhibitors (TKIs).1-3 Currently, multiple TKIs have
been introduced in the treatment of solid tumours.4 All TKIs are
administered orally at a flat-fixed dose, although large interpatient
pharmacokinetic (PK) variability is described.5-8 Retrospective
analyses demonstrated an exposure-treatment outcome (efficacy
and toxicity) relationship for imatinib, pazopanib and sunitinib
across tumour types.9-13 More and more data show that a mini-
mum target level of drug exposure should be achieved to gain
optimal treatment benefit. Dose reductions during treatment are
mainly driven by toxicity and relationships between exposure and
toxicity have also been described. Upper limits have been defined
above which toxicity is more frequently seen.6,9,12 These thresholds
for efficacy and toxicity have been defined either by constructingThe participating centres and members of the DPOG are listed in the appendix.
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receiver operating characteristics curves or by evaluating the rela-
tion between quartile or decile drug trough levels and treatment
outcome. It has been suggested that a more personalized dose
should be used to address the issue of the large interpatient PK
variability leading to more treatment benefit and preventing unnec-
essary toxicity.14,15
Dose optimization based on measured blood concentration is
called therapeutic drug monitoring (TDM) and can be valuable for
drugs with a small therapeutic window, an established exposure–
response relationship and large interpatient PK variability, all applica-
ble for TKIs.16 TDM guided dosing is routinely used for anti-epileptics,
antibiotics, immunosuppressive agents and within oncology for
methotrexate (MTX), mitotane and busulfan,17-21 but is less common
for TKIs despite a similar level of available evidence that optimizing
the dose will result in less toxicity or better efficacy.22 For an increas-
ing number of TKIs a target threshold has been defined and TDM
based dosing seems promising.23,24 For imatinib, sunitinib and
pazopanib, TDM is even considered viable since studies have shown
the feasibility of TDM to reach drug levels within the therapeutic win-
dow.12,15,25-27 Despite increasing evidence, the routine use of TDM in
patients treated with imatinib, pazopanib and sunitinib is still not
embedded in patient care.
In this review we present an overview of the current knowledge
on TDM guided individualized dosing of imatinib, sunitinib and
pazopanib for the treatment of solid tumours. For this purpose, we
summarize preclinical and clinical data that have defined thresholds
for efficacy and toxicity. Furthermore, we describe factors that influ-
ence the PK of these drugs and factors identified by population PK
model studies that possibly explain the interpatient PK variability.
Finally, we present pharmacological interventions that have been per-
formed to optimize concentrations of these three agents.
2 | METHODS
2.1 | Search strategy
We performed an electronic systematic search of the PubMed data-
base to 18 July 2019 using predefined terms (including Medical Sub-
ject Headings (MeSH) terms). Papers were included if they were
available in full text and English language. We only included papers
that focused on imatinib, sunitinib or pazopanib in solid tumours and
excluded papers that focused on imatinib in chronic myeloid leukae-
mia (CML). Our main focus was on clinical studies performed in
humans. All titles and abstracts were screened. The references of key
articles were additionally screened and relevant papers were included
in this review. The search strategy and results are presented in the
Supporting Information.
2.2 | Results
Performing the electronic search on PubMed resulted in a total of 454
papers, of which 82 papers were eligible for inclusion in this review.
Another 41 papers were selected by screening the references of the
key articles.
2.3 | Defining the optimal clinical threshold
2.3.1 | Imatinib
Imatinib inhibits BCR-ABL, platelet-derived growth factor receptor
(PDGFRα-β) and cytokine receptor (c-KIT).28,29 It is approved for the
treatment of CML and gastrointestinal stromal tumour (GIST).30-32 As
our review focuses on solid tumours we only discuss imatinib in GIST.
The development of GIST is associated with several gain-of-function
mutations in c-KIT and PDGFR.33
Preclinical thresholds for response
In vitro studies showed that the inhibition of PDGFR and c-KIT
is concentration-dependent, requiring an imatinib concentration of
49.4-493.6 ng/mL.34,35 The concentration of imatinib that produces
50% inhibition (IC50) of both PDGFR and c-KIT is 49.4 ng/mL.
34,35
Complete inhibition of c-KIT was observed at a concentration of
493.6 ng/mL.35 Since 36-70% of small cell lung cancer (SCLC)
tumours express c-KIT, the effect of imatinib was investigated
in human SCLC xenografts. Growth inhibition of 40-80% was
observed.36
Clinical thresholds for response
Exposure–response relationship. Details of studies evaluating the
exposure–response relationship in patients treated with imatinib are
presented in Table 1. In patients with advanced or metastatic GIST,
who were treated with imatinib 400 mg once-daily (OD), mean plasma
trough level (Ctrough) was higher in patients who responded to treat-
ment. Response was defined either as longer time to progression
(TTP) or as radiological response according to Response Evaluation
Criteria In Solid Tumours (RECIST).12,37 A target threshold of
>1,100 ng/mL has been defined.12,37,38 These results are similar to
results previously found in patients with CML.10,46,47 One study in 96
patients with GIST reported a lower threshold of 760 ng/mL.39 How-
ever, they measured Ctrough after ≥3 months of treatment and a
29.3% decrease in imatinib exposure in the first 3 months of treat-
ment, which corresponds to the lower threshold defined in this study,
was previously observed.48
Since patients receiving adjuvant imatinib after resection are
treated with 400 mg OD as well and it targets the same tumour cells,
it seems reasonable to maintain the same threshold of >1100 ng/mL
in the adjuvant setting.
Some studies have demonstrated that a dose of 400 mg twice-
daily (BID) was correlated with a longer progression-free survival
(PFS) compared to 400 mg OD.49-52 This applied in particular to
patients with a c-KIT exon 9 mutation, in whom reported outcome
was worse compared to patients with a mutation in exon 11.53-55
Although the evidence is limited, it is currently advised by the ESMO
guidelines to treat patients with a c-KIT exon 9 mutation at a dose of
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400 mg BID.51,56 No data on plasma concentrations are available in c-
KIT exon 9 mutated GIST treated with imatinib 400 mg BID. Taking
into account the dose proportional relationship, a threshold of
>2200 ng/mL for imatinib 400 mg BID could be considered.57 Cur-
rently, there are no threshold recommendations for patients with a
mutation in PDGFR or wild-type tumour genotype.
In the metabolism of imatinib, an active metabolite (N-desmethyl-
imatinib, CGP74588) is formed with similar pharmacological activity
that accounts for 16% of the area under the curve (AUC) of
imatinib.31,58 However, since the active metabolite represents a mod-
est amount of the total exposure, studies that examined the
exposure–response relationships have focused on imatinib alone.
Exposure–toxicity relationship. Higher exposure is associated with
increased toxicity (Table 1).5,10,37 However, since imatinib is a rela-
tively well-tolerated TKI, limited data is available on the upper limit of





measure Relationship P value References
Imatinib GIST Ctrough ≥ 1100 ng/mL TTP Responseà higher Ctrough (1446 ng/mL vs
1155 ng/mL)
Higher Ctroughà longer TTP
Ctrough ≥ 1100 ng/mLà better OOBR










Higher free imatinibà more response
Higher total + free imatinibà higher incidence
AEs
0.026 37
GIST - Response Responseà higher Ctrough (1271 ng/mL vs
920 ng/mL)
NS 38
GIST Ctrough ≥ 760 ng/mL PFS Ctrough ≥ 760 ng/mLà longer PFS (PFS not
reached vs 56 months)
0.0256 39
GIST - Toxicity Higher free imatinibà higher incidence
neutropenia
P < 0.001 5
Sunitinib Various Ctrough > 50 ng/mL Efficacy
Toxicity
Patients with ORà received doses ≥50 mg OD
Dose of 50 mg ODà Ctrough 50-100 ng/mL
Patients with DLTà Ctrough > 100 ng/mL
… 6
RCC + GIST - Efficacy
Toxicity
RCC: Higher sunitinib levelà longer TTP
GIST: Higher sunitinib levelà longer TTP





RCC Ctrough < 100 ng/mL Toxicity Ctrough ≥ 100 ng/mLà higher incidence toxicity
(75% vs 23.1%)
… 40
RCC Toxicity Patients who discontinue treatmentà higher
Ctrough
… 41
RCC Toxicity Higher sunitinib levelà higher incidence AEs 42
Pazopanib RCC Ctrough > 20.5 mg/L PFS Ctrough > 20.5 mg/Là longer PFS (52.0 vs
19.6 weeks)
0.00378 9




Ctrough > 20 mg/L PFS RCC: Ctrough > 20 mg/Là longer PFS (34.1 vs
12.5 weeks)





- Toxicity Higher Ctroughà more patients discontinue
treatment
…
RCC Ctrough > 20.5 mg/L Response Ctrough < 20.5 mg/Là no OR …
44
Ctrough < 50.3 mg/L Toxicity Grade ≥ 3 toxicitiesà higher Ctrough (69.3 mg/L
vs 41.2 mg/L)
Ctrough ≥ 50.3 mg/Là higher incidence toxicity
(61.5% vs 7.1%)
P < 0.05
RCC Ctrough > 20.5 mg/L DFS Ctrough > 20.5 mg/Là longer DFS 0.0078
45
AE, adverse event; CML, chronic myeloid leukaemia; Ctrough, plasma trough level; DFS, disease-free survival; DLT, dose-limiting toxicity; GIST,
gastrointestinal stromal tumour; NS, non significant; OD, once a day; OOBR, overall objective benefit rate (complete response + partial response + stable
disease); OR, objective response; PFS, progression free survival; RCC, renal cell carcinoma; STS, soft tissue sarcoma; TTP, time to progression.
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dosing in the view of toxicity. One study in patients with CML
described an association between haematologic adverse events (AEs)
and an imatinib Ctrough > 3180 ng/mL.
10 This has not been confirmed
by other studies yet.
Conclusion
Based on previous studies in which response to imatinib treatment
was correlated with imatinib exposure of >1100 ng/mL, we recom-
mend a target imatinib exposure threshold of >1100 ng/mL in
patients with c-KIT exon 11 mutated GIST who are treated with
400 mg OD. For c-KIT exon 9 mutated GIST, treated with a dose of
400 mg BID and considering the linear dose-exposure relationship, a
threshold of >2200 ng/mL might be considered.
2.3.2 | Sunitinib
Sunitinib is an inhibitor of PDGFRα-β, vascular endothelial growth
factor receptor (VEGFR1-2), fetal liver tyrosine kinase receptor 3
(FLT3) and c-KIT, and is registered for the treatment of renal cell carci-
noma (RCC), GIST and neuroendocrine tumours.59,60
Preclinical and early phase clinical thresholds for response
Preclinical studies in mouse xenograft models and in small cell lung
cancer cell lines have shown that the inhibition of VEGFR, PDGFR
and c-KIT by sunitinib requires a plasma concentration of
50-100 ng/mL.61,62 In a phase I study, including patients with RCC or
GIST, all patients with an objective response (OR) received doses of
sunitinib of ≥50 mg OD 4 weeks on, 2 weeks off (4/2).6 An increase
in dose led to a linear increase in Ctrough and doses of 50 mg OD
resulted in Ctrough ranging from 50 to 100 ng/mL. All responders had
sunitinib Ctrough > 50 ng/mL. Dose limiting toxicity (DLT) was experi-
enced at a dose ≥75 mg OD with Ctrough ≥ 100 ng/mL.
6
Patients with GIST are generally treated at a lower but con-
tinuous dose of sunitinib of 37.5 mg OD. Several studies have
shown, albeit not in a head-to-head comparison, that this results
in similar PFS but less toxicity when compared to a dose of
50 mg OD 4/2.63,64
In the metabolism of sunitinib, an active metabolite
(desethylsunitinib, SU012662) is produced with similar potency as
sunitinib. Since SU012662 accounts for 23-37% of the total exposure
at steady state, this metabolite contributes to the anti-tumour effect
of sunitinib,6,59,65 therefore sunitinib exposure–response relationships
are studies based on the sum Ctrough (sunitinib + SU012662).
Clinical thresholds for response
Exposure–response relationship. The details and findings of studies
evaluating the relationship between exposure and treatment outcome
for sunitinib are shown in Table 1.
Houk et al demonstrated in 443 patients that sunitinib exposure
above the median AUC was correlated with improved clinical outcome
in patients with RCC or GIST.11 Previously it was shown that sum
Ctrough and AUC are highly correlated.
66 The reported median sum
Ctrough in patients treated with sunitinib 50 mg OD is between 50 and
84 ng/mL,6,59,67 therefore the findings of Houk et al support a target
threshold for sum Ctrough of >50 ng/mL for a dose of 50 mg OD 4/2.
In order to manage toxicity, an alternate schedule with sunitinib
50 mg OD 2 weeks on, 1 week off (2/1) has been investigated as well,
resulting in comparable complete or partial response, but superior tol-
erability.68 Since the sunitinib dose is similar in this treatment sched-
ule, a steady-state threshold of sunitinib sum Ctrough > 50 ng/mL can
be advised here as well. Considering the linearity of dose with Ctrough,
a threshold for sum Ctrough of >37.5 ng/mL has been advised for treat-
ment with 37.5 mg OD continuous dosing.69
Exposure–toxicity relationship. Following Faivre et al, who described
DLT at sum Ctrough ≥ 100 ng/mL, four other studies described a corre-
lation between a high Ctrough and the occurrence of AEs.
6,11,40-42
Two studies described treatment discontinuation for AEs at sum
Ctrough > 75 ng/mL and > 100 ng/mL, respectively.
40,41
Interestingly, toxicity also seems to be related to the country
where patients are treated Lee et al. described substantial differences
in the incidences of various AEs between Asian patients who were
treated in Asia or in countries outside of Asia.70
Conclusion
In conclusion, since sunitinib sum Ctrough > 50 ng/mL is associated
with clinical response, we recommend a target exposure threshold for
sunitinib sum Ctrough of >50 ng/mL for intermittent dosing (50 mg OD
4/2 or 2/1). Taking into account the dose proportional relation for
sunitinib, we recommend a threshold of >37.5 ng/mL for continuous
dosing (37.5 mg OD). Toxicity increases above sunitinib sum Ctrough
levels of >87.5 ng/mL and > 75 ng/mL for intermittent and continu-
ous dosing, respectively.
2.3.3 | Pazopanib
Pazopanib is an inhibitor of VEGFR1-2-3, PDGFRα-β and c-KIT.71
Pazopanib is used for the treatment of RCC and soft tissue sarcoma
(STS).72-74
Preclinical and early-phase clinical thresholds for response
In preclinical studies with multiple myeloma cells and mouse xenograft
models, the antitumor and antiangiogenic activity of pazopanib is
concentration-dependent, requiring a steady-state plasma concentra-
tion of >40 μmol/l (= 17.5 mg/L).75,76 In a phase I dose-escalating trial
in which patients received doses ranging from 50 mg three times
weekly to 2000 mg OD and 300-400 mg BID, effectiveness of
pazopanib in patients with metastatic RCC was correlated with a
pazopanib Ctrough of ≥15 mg/L.
7 The patients with clinical response
received doses of ≥800 mg OD or 300 mg BID. The maximum toler-
ated dose (MTD) was not reached, but the exposure to pazopanib did
not increase at a dose of ≥800 mg OD, therefore the recommended
dose was defined as 800 mg OD with predefined dose reductions in
case of unacceptable toxicity.7
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Pazopanib also has active metabolites that together represent
approximately 6% of the total drug exposure.77 In accordance with
imatinib, these metabolites were not measured in studies examining
the relationship between exposure and outcome.
Clinical thresholds for response
Exposure–response relationship. Clinical studies on the exposure–
effectiveness relationship for pazopanib are presented in Table 1.
Suttle et al defined a pazopanib threshold Ctrough > 20.5 mg/L to be
correlated with a significant increase in median PFS in patients
with RCC.9 Patients below this threshold showed comparable efficacy
to placebo. This threshold approximates the findings in the
preclinical/early-phase trials and was confirmed independently by
Verheijen et al.13 Although differences in response at the same
threshold were seen for patients with STS, the difference did not
reach statistical significance, potentially due to the limited number of
patients and the more modest effect size in patients with STS com-
pared to mRCC,13 therefore, although less robust, the same threshold
might be applicable for patients with STS.13
Not only survival but also response rates (assessed using the
RECIST criteria) have been correlated with pazopanib trough levels;
out of 27 RCC patients, none of the three patients with a pazopanib
Ctrough < 20.5 mg/L experienced an OR, while 11 out of the remaining
24 patients showed OR.44
Exposure–toxicity relationship. The relationship between exposure
and toxicity has also been established9,13,43,44 (overview Table 1),
showing that increasing pazopanib Ctrough is associated with
increased incidence of AEs.9,13 Two studies (n = 205) calculated
that the highest incidence of AEs occurred in patients with a
pazopanib Ctrough > 46 mg/L, especially for hand-foot syndrome
and hypertension (all grades).9,43 Noda et al (n = 27) recently calcu-
lated a nearly similar upper threshold of ≥50.3 mg/L for grade ≥ 3
toxicity.44 Results were most convincing for fatigue, anorexia and
hypertension.
Conclusion
In several clinical studies, a pazopanib Ctrough > 20.5 mg/L is corre-
lated with a significant increase in median PFS, therefore we recom-
mend a target exposure threshold for pazopanib Ctrough of
>20.5 mg/L. More toxicity is reported in patients with pazopanib
Ctrough levels >46 mg/L.
2.4 | Explaining interpatient variability in
pharmacokinetics
2.4.1 | Imatinib
Imatinib shows dose proportional PK and high interpatient variability
(38-78%), though modest intrapatient variability (21-35%).10,38,39 A
summary of the PK parameters of imatinib is shown in Table 2.
Factors identified in pharmacokinetic models that explain
interpatient variability
Many population PK model studies for imatinib have been published,
describing imatinib PK as a one-compartment model with zero- or
first-order absorption and first-order elimination.5,12,83,98-104 Many
covariates were explored, some of which showed significant correla-
tions with imatinib exposure.
A higher level of alpha-acid glycoprotein (AAG) is correlated with
a lower clearance of imatinib in multiple studies.5,100,105 Some PK
models describe a positive correlation between imatinib clearance and
body weight.83,98-100 Single nucleotide polymorphisms (SNPs) in
ABCB1 (1236 T > C, 2766G > T/A and 3435C > T), SLCOB3 (SLOCB3
334GG genotype) or CYP3A5 (eg CYP3A5*3) are potentially also asso-
ciated with imatinib clearance and can increase imatinib clearance by
36-61%.102-104 Furthermore, one study described a 45% reduction in
dose-adjusted imatinib Ctrough in patients with a SNP in CYP3A4
(20239G > A allele or 20239G > A homozygote).106 One study reported
a significant association between SNPs in ABCG2 and CYP1A2 and
the need for dose reductions, although no imatinib exposure was
measured.107
An observation in one study is that imatinib exposure
decreased by 29.3% in the first 3 months after the start of therapy
(n = 50).48 Several hypotheses have been proposed to explain this
finding, for example reduced bioavailability of imatinib.48 Another
hypothesis could be that reduced imatinib exposure is caused by a
decrease in AAG level, since imatinib is mainly bound to AAG, as a
consequence of the reduction of inflammation after the start of
imatinib.108 However, this hypothesis could not be confirmed by
Bins et al, who observed no decrease in AAG level during imatinib
treatment.109 The observation of a decrease in imatinib exposure
was not supported by two other studies (n = 108 and n = 65).38,97
However, one of those studies measured the initial imatinib Ctrough
after patients had been treated with imatinib for a median time of
5.5 months.97
Other factors that influence pharmacokinetics
Major gastrectomy has been shown to significantly lower imatinib
exposure.110,111 However, no significant correlation between the use
of proton pump inhibitors and imatinib exposure was found.14
Conflicting results are reported for the influence of renal function
on imatinib pharmacokinetics, with some studies describing higher
imatinib AUCs in patients with renal dysfunction, while other studies
describe no correlation.5,12,105,110 Since imatinib is predominantly
eliminated by the liver, it was hypothesized that renal failure causes
decreased cytochrome P450 activity, thereby increasing systemic
exposure to imatinib.105 Another explanation might be that patients
with end-stage renal disease have increased levels of uremic toxins,
which can inhibit the uptake of imatinib in hepatocytes.112 Co-
medication inducing CYP3A4 can cause a significant decrease in
imatinib exposure.14 However, van Erp et al demonstrated that at
steady state, imatinib is insensitive to CYP3A4 inhibition.88 This might
be explained by other metabolic pathways that are predominantly
used at steady-state pharmacokinetics due to auto-inhibition of
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CYP3A4 metabolism by imatinib, for example CYP2D6, which is
known to play a role in imatinib metabolism.31,88
Conclusion
Imatinib clearance can be affected by body weight and AAG level.
Imatinib exposure is significantly lower in patients who underwent
major gastrectomy. Furthermore, renal function and SNPs in
ABCB1, SLCOB3, CYP3A4 or CYP3A5 can significantly alter
imatinib exposure. Although the mechanism remains unknown,
some studies describe a decrease in imatinib exposure in the first
months after start of treatment, therefore imatinib exposure should
be measured after the start of therapy and repeated at least after
three months.
2.4.2 | Sunitinib
Similar to imatinib, sunitinib shows dose proportional PK, large inter-
patient PK variability (34-60%) and modest intrapatient PK variability
(29-52%).59,60,96 PK parameters of sunitinib are shown in Table 2.
Factors identified in pharmacokinetic models that explain
interpatient variability
For sunitinib, several population PK models have been devel-
oped.96,113-120 The PK of sunitinib and SU012662 is described as a
one- or two-compartment model with first-order absorption and elim-
ination. Some covariates might explain part of the interpatient PK
variability.
TABLE 2 PK parameters of imatinib, pazopanib and sunitinib
PK








soluble at pH < 4)
8,82
Tmax (h) 2-4
57,78 6-12 60,65 2-4 82
Protein
binding (%)





435 78 2200 65 9-13 82,85
Penetration of
blood–
brain-barrier Imatinib concentration in CSF
is 40- to 100-fold









Metabolism Mainly by CYP3A4 and
CYP3A5, to a lesser
extent by CYP2D6






CGP74588 ± 10% of
AUC of imatinib
91 Equipotent metabolite
SU012662 ± 21% of
AUC of sunitinib






8.48-9.06 30,58 37.2 59 0.21-0.35 2,92





Excretion Mainly through faeces 31,91 Faeces: 50-72%
Urine: 13-20%










21-35 10,38,39,46,97 29-38% for sunitinib
38-52% for SU012662
60 75 8
AUC, area under the curve; CSF, cerebrospinal fluid; PK, pharmacokinetic; Tmax, time to reach maximum plasma concentration.
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SNPs in ABCG2 (eg ABCG2 421 C > A) and ABCB1 were found to
be significantly correlated with sunitinib clearance.115,118,119 Sunitinib
clearance is decreased by 12-15% in Asian patients compared to non-
Asian patients.113,116 This might partly be explained by a higher preva-
lence of the ABCG2 421 C > A genotype in Asian patients.121 The
effect of CYP3A4*22 was also studied and resulted in a 22.5% lower
clearance of sunitinib.120 CYP3A5*1 has been associated with an
increased risk of dose reductions of sunitinib in several studies.122,123
No sunitinib levels were measured, but considering the exposure–
toxicity relationship, it is reasonable to assume that CYP3A5*1 results
in lower sunitinib clearance.
Several studies have shown that sunitinib clearance decreases
with decreasing body weight, body surface area and lean body
mass.113,117,119 Also, increasing age causes a slight decrease in sun-
itinib clearance of 0.7% per year.116 Finally, sunitinib clearance is
decreased in women compared to men.113,116 However, considering
the minor effects of these clinical characteristics on sunitinib PK, no
adjusted dose is advised.65
Other factors that influence pharmacokinetics
Co-medication inducing or inhibiting CYP3A4 can cause a significant
decrease or increase in sunitinib exposure of 46% and 51%, respec-
tively.65 Furthermore, consumption of grapefruit juice results in an
11% increase in sunitinib exposure, which is not considered clinically
relevant.124
There is no necessity for dose adjustments in patients with renal
or mild to moderate hepatic impairment.65,125,126
Conclusion
Sunitinib clearance is affected by weight, gender and race, although
effects are limited and adjustments of the starting dose are not
recommended based on these patient characteristics. Both
CYP3A4*22 and CYP3A5*1 can significantly lower sunitinib
clearance, although the occurrence of these alleles is rare.
Co-medication inducing or inhibiting CYP3A4 can significantly
decrease or increase sunitinib exposure by 50%. This can poten-
tially lead to under- or overdosing of sunitinib, which might result
in decreased treatment efficacy or increased toxicity. However,
considering the comorbidities of patients, it is not always possible
to discontinue treatment with co-medication interacting with
CYP3A4, therefore TDM should be considered as an elegant tool
to monitor the exposure to sunitinib in order to be able to con-
tinue treatment with sunitinib and CYP3A4 inducers or inhibitors
simultaneously.
2.4.3 | Pazopanib
Pazopanib has challenging PK characteristics with, for example, satu-
rated absorption and low bioavailability. Multiple studies have shown
that there is large intra- and interpatient variability (75% and 36-67%,
respectively) in the PK of pazopanib.7,13,25,127 A summary of the PK
parameters of pazopanib is shown in Table 2.
Factors identified in pharmacokinetic models that explain
interpatient variability
In order to be able to understand the PK characteristics of pazopanib
and to investigate the influence of different factors (covariates), popu-
lation PK models for pazopanib have been developed.8,128-130 Some
covariates were identified that explain part of the interpatient variabil-
ity observed.
The registration file of the Food and Drug Administration (FDA)
for pazopanib mentioned that in patients with an Eastern Cooperative
Oncology Group (ECOG) score of 1, pazopanib clearance increased by
14% compared to patients with an ECOG score of 0.77 Although con-
tradictive, this observation was recently confirmed in PK data analysis
of the PROTECT study where more patients had an ECOG score of 0
and pazopanib Ctrough levels were higher, compared to historical
data.45
Bins et al reported that the SNP in CYP3A4 which was also
related to sunitinib clearance, namely CYP3A4*22, resulted in a
decreased clearance of pazopanib of 35%.130
Finally, two PK models described saturated absorption of
pazopanib and a 40-59% higher relative bioavailability for a dose of
400 mg compared to 800 mg.8,129 Furthermore, these models
observed that the exposure of pazopanib decreases in the first 4 weeks
after start of treatment with ~25%.8,129 This observation is in line with
findings in an earlier study.127 The mechanism behind the decrease
in exposure over the first few weeks has not been clarified yet.
Other factors that influence pharmacokinetics
Based on PK drug interaction studies, other factors have been identi-
fied that also influence pazopanib PK. Food has a major effect on the
absorption of pazopanib. Heath et al demonstrated that pazopanib
exposure increased two-fold with the intake of a high-fat or low-fat
meal.131 Pazopanib is primarily metabolized by the liver. In patients
with moderate or severe hepatic dysfunction, the maximum tolerated
dose was only 200 mg OD. Since this dose resulted in subtherapeutic
exposure, pazopanib is not recommended in patients with moderate
or severe hepatic dysfunction.132,133 Finally, Tan et al reported a
significant increase in pazopanib exposure in patients using co-
medication inhibiting CYP3A4 and a significant decrease in pazopanib
exposure in patients using concomitant pH-elevating medication.134
Yu et al incorporated this latter observation in their PK model,
suggesting the absorption of pazopanib could best be described by a
fast absorption process in the stomach and duodenum, where pH is
low, followed by a slower process in the latter part of the intestine,
where pH rises.8
Conclusion
PK model studies have shown that ECOG score and CYP3A4*22
genotype explain part of the interpatient variability in pazopanib PK.
Furthermore, a saturated absorption of pazopanib and a decrease in
pazopanib exposure at the beginning of treatment were observed.
Finally, the concomitant intake of food, gastric acid reducing agents
and the use of co-medication affecting CYP3A4 activity can lead to
clinically relevant changes in pazopanib exposure.
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2.5 | Dose optimization strategies to reach
threshold
For imatinib, sunitinib and pazopanib, thresholds have been
established above which more treatment benefit and toxicity, respec-
tively, are observed.6,9,11,12 For an overview of the recommended
thresholds for imatinib, sunitinib and pazopanib, see Table 3. There-
fore, TDM guided dose interventions might be a valuable tool to opti-
mize individual drug exposure in order to maximize the number of
patients treated effectively and to decrease the number of patients
suffering from toxicity.135 This applies particularly for imatinib and
sunitinib, where low intrapatient PK variability is observed. This, how-
ever, is more challenging for pazopanib considering its large
intrapatient PK variability. In the next part of the review the pharma-
cological tools available to optimize the plasma levels of imatinib,




For imatinib, one study has evaluated the feasibility of TDM in achiev-
ing the target exposure threshold of >1100 ng/mL in patients with
GIST.15 This study in 68 patients demonstrated the feasibility of TDM
in achieving the target exposure threshold, although physician adher-
ence to dose recommendations was low (~54%).15 However, 95% of
patients in whom dose intervention was implemented achieved ade-
quate imatinib Ctrough.
Other interventions
It has previously been demonstrated that imatinib exposure signifi-
cantly decreases after gastrectomy.110 It was therefore investigated
whether co-administration of imatinib with an acidic beverage could
increase the exposure to imatinib. This was previously described for
erlotinib,140 but could not be substantiated for imatinib.141
2.5.2 | Sunitinib
Dose interventions
Two studies were published evaluating the feasibility of TDM guided
dosing to reach adequate drug levels for patients treated with
sunitinib.15,136
Lankheet et al reported that in 5/5 patients with an initial Ctrough
below the threshold of 50 ng/mL and the absence of severe toxicity,
dose was successfully increased without increasing toxicity, resulting
TABLE 3 Exposure thresholds for efficacy and toxicity for
imatinib, sunitinib and pazopanib
Drug Threshold efficacy Threshold toxicity









Pazopanib >20.5 mg/L <46 mg/L
TABLE 4 Interventions to reach threshold for imatinib, sunitinib and pazopanib
Drug Intervention Findings References
Imatinib Dose interventions Patients with TDM guided increase in dose 95%
adequate Ctrough
15
Sunitinib Dose interventions Patients with TDM guided increase in dose 76-100%
adequate Ctrough
15,136
Pazopanib Dose intervention Patients with TDM guided increase in dose 70%
adequate Ctrough
Patients with TDM guided decrease in dose 78%
reduction in toxicity
Interpatient variability 71.9% 33.9%
15,25,137
Food interventions AUC doubled with both high-fat FDA meal and low-fat
FDA meal.
131
600 mg pazopanib with continental breakfast
bioequivalent to 800 mg fasted
138
Crushed tablet or oral suspension Crushed tablet increase in AUC of 46%
Interpatient variability 72.5% 26.8%
Oral suspension increase in AUC of 33%.
Splitting the dose Relative bioavailability of 400 mg 40-59% higher
compared to 800 mg.
8,77
400 mg BID instead of 800 mg OD increase in Ctrough
of 52%
139
AUC, area under the curve; BID, twice a day; Ctrough, plasma trough level; FDA, Food and Drug Administration; OD, once a day; TDM, therapeutic drug
monitoring.
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in an adequate sunitinib Ctrough.
136 Another study demonstrated that
of 17 patients in whom the recommended dose adjustment was
implemented, 13 patients (~77%) reached adequate Ctrough of
>50 ng/mL after dose adjustment.15 Furthermore, the percentage of
patients with a sunitinib Ctrough above threshold increased from ~48%
to ~74% with TDM guided dosing.15
Several case reports have reported on the added value of TDM
guided dosing to reduce toxicity, for instance in vulnerable patients
with extensive comorbidity (eg haemodialysis, previous bariatric sur-
gery or cardiac transplantation).142-145
CYP3A4 boosting
A significant increase in sunitinib exposure was observed when
co-administering sunitinib with CYP3A4 inhibitors.65 This might
therefore be a tool to increase exposure to sunitinib without
increasing the dose, as for protease inhibitors in patients with HIV,




Several studies have evaluated the feasibility of TDM in the treatment
of patients with solid tumours with pazopanib.15,25,127
One study could not establish the feasibility of TDM for
pazopanib in 13 patients due to large intrapatient variability.127 How-
ever, two other studies (n = 30 and n = 12) demonstrated that the
number of patients reaching adequate pazopanib Ctrough can be
increased by 50% by using TDM.15,25
Food interventions
Heath et al demonstrated a higher exposure to pazopanib when
administering pazopanib concomitant with food.131 Thereafter, it was
demonstrated that a lower dose of pazopanib can be administered
with food while maintaining bio-equivalent Ctrough levels of a higher
dose without food (n = 78) while gastrointestinal toxicity was compa-
rable when a reduced dose of pazopanib was taken with food.138
Recently, another study reported that administering pazopanib with
food did not increase the risk of toxicity (n = 16), while all but two
patients reached adequate Ctrough.
147 Not having to fast around the
pazopanib intake may positively affect quality of life for cancer
patients, especially those experiencing difficulty in maintaining
bodyweight. The preference of patients for intake with food was
shown in the DIET study where 68% of patients preferred the intake
of pazopanib with food compared to without food.138
Gastric pH
Two studies reported shorter PFS and overall survival (OS) in patients
treated with pazopanib receiving concomitant pH-elevating medica-
tion, though in one of these studies the effect on treatment outcome
was not statistically significant.148,149 Unfortunately, no pazopanib
plasma concentrations were measured. However, considering the
essential role of gastric pH in the absorption of pazopanib and the
previously established decrease in pazopanib AUC when combined
with a proton pump inhibitor, it is likely that the shortened survival is
caused by underexposure to pazopanib.134
Crushed tablet or oral suspension
Administering pazopanib as a crushed tablet or an oral suspension
increases the AUC by 46% and 33%, respectively, and decreases the
interpatient PK variability from ~73% to ~27%.150 For a significant
amount of patients with cancer it can be difficult to swallow whole
tablets and this might be a good alternative.
Splitting the dose
Previous studies and simulations have described a saturated absorp-
tion of pazopanib and a higher relative bioavailability for lower dos-
ages.7,8,77 Recently, the effect on exposure levels of splitting the dose
of pazopanib was investigated.139 It was demonstrated that adminis-
tering pazopanib 400 mg BID led to an increase of Ctrough of 52%
compared to 800 mg OD (n = 10). Splitting the dose might be a good
tool to increase pazopanib exposure in patients underdosed with
800 mg OD.
CYP3A4 boosting
Since a significant increase in pazopanib exposure was observed in
patients using co-medication inhibiting CYP3A4, this might be an
alternative approach to optimize pazopanib plasma levels, though this
has not been investigated yet.134
Conclusion
For imatinib and sunitinib, the optimal method for dose optimization
is to adjust the dose according to measurements of Ctrough. Consider-
ing the large interpatient PK variability compared to intrapatient PK
variability it is advisable to monitor plasma Ctrough levels after the start
of therapy and after dose adjustments.
Reaching the exposure threshold of pazopanib by dose incre-
ments only might be challenging due to the complex absorption pro-
file of pazopanib and the large intrapatient PK variability. A variety of
alternative methods is available to influence pazopanib plasma trough
levels and potentially reduce the significant intrapatient variability.
Currently, peer-reviewed data has been published on administering
pazopanib concomitant with food. However, regardless of the method
used to optimize pazopanib exposure, it is of the utmost importance
that the effect of any intervention is monitored with plasma Ctrough
levels measurement.
2.6 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY 151, and are permanently archived in the Concise Guide to
PHARMACOLOGY 2016/2017: overview152.
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3 | CONCLUSION
For imatinib, sunitinib and pazopanib, an exposure–outcome relation-
ship has been demonstrated and the concentration thresholds to opti-
mize efficacy and minimize toxicity (therapeutic window) have been
defined. It has been demonstrated that the percentage of patients
with drug levels within the predefined target range is low for all three
anti-cancer agents, ranging from 27% to 52%. It has therefore been
suggested that TDM guided dosing can result in a higher efficacy and
lower toxicity rate. The feasibility of TDM guided dosing and of
reaching target drug exposure with TDM guided dosing has been
shown for imatinib, sunitinib and pazopanib.
For imatinib and sunitinib, considering the relatively small
intrapatient PK variability, TDM guided dosing can be a valuable tool
to optimize individual exposure to these drugs in order to either maxi-
mize the effect by increasing the dose or reduce toxicity by decreas-
ing the dose. For pazopanib, however, reaching the target range by
dose adjustments might be more challenging due to large intrapatient
PK variability. Based on the available literature, food should be con-
sidered as an intervention to reach the target threshold. Another
approach to examine could be to boost pazopanib exposure by using
CYP3A4 inhibitors or splitting the pazopanib dose.
Regardless of the intervention applied to optimize exposure to
these drugs, it is of the utmost importance to measure drug levels
after interventions and troughout treatment to carefully monitor the
effect of any intervention.
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APPENDIX A: | Participating centres and members of the
Dutch Pharmacology and Oncology Group (DPOG)
DPOG centres
The Netherlands Cancer Institute, Antoni van Leeuwenhoek,
Amsterdam, the Netherlands
Erasmus MC Cancer Institute, University Medical Center Rotter-
dam, Rotterdam, the Netherlands
Leiden University Medical Center, Leiden, the Netherlands
University Medical Center Groningen, Groningen, the
Netherlands
Radboud University Medical Center, Nijmegen, the Netherlands
DPOG board members
Dr N. Steeghs, Medical Oncologist and Clinical Pharmacologist1
Prof. dr. A.D.R. Huitema, Hospital Pharmacist and Clinical
Pharmacologist2,3
Prof. dr. A.H.J. Mathijssen, Medical Oncologist and Clinical
Pharmacologist4
Prof. dr. A.J. Gelderblom, Medical Oncologist5
Prof. dr. A.K.L. Reyners, Medical Oncologist6
Dr N.P. van Erp, Hospital Pharmacist and Clinical Pharmacologist7
DPOG members
Dr S.L.W. Koolen, Hospital Pharmacist and Clinical
Pharmacologist4,8
Dr D.J.A.R. Moes, Hospital Pharmacist9
Prof. dr. D.J. Touw, Hospital Pharmacist and Clinical
Pharmacologist10
Dr I.M.E. Desar, Medical Oncologist11
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